Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension : a population-based study

José A Barrabés, Ignacio Ferreira-Gonzalez, María José Soler, Aida Ribera, Josep Ramon Marsal, Ana Belen Méndez, Mireia Andrés Villareal, María A Azancot, Gerard Oristrell, Leonardo Méndez-Boo, Jordana Cohen

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)

Abstract

The effect of renin-angiotensin system (RAS) blockade either by angiotensin-converting enzyme inhibitors (ACEis) or angiotensin-receptor blockers (ARBs) on coronavirus disease 2019 (COVID-19) susceptibility, mortality and severity is inadequately described. We examined the association between RAS blockade and COVID-19 diagnosis and prognosis in a large population-based cohort of patients with hypertension (HTN). This is a cohort study using regional health records. We identified all individuals aged 18-95 years from 87 healthcare reference areas of the main health provider in Catalonia (Spain), with a history of HTN from primary care records. Data were linked to COVID-19 test results, hospital, pharmacy and mortality records from 1 March 2020 to 14 August 2020. We defined exposure to RAS blockers as the dispensation of ACEi/ARBs during the 3 months before COVID-19 diagnosis or 1 March 2020. Primary outcomes were: COVID-19 infection and severe progression in hospitalized patients with COVID-19 (the composite of need for invasive respiratory support or death). For both outcomes and for each exposure of interest (RAS blockade, ACEi or ARB) we estimated associations in age-, sex-, healthcare area- and propensity score-matched samples. From a cohort of 1 365 215 inhabitants we identified 305 972 patients with HTN history. Recent use of ACEi/ARBs in patients with HTN was associated with a lower 6-month cumulative incidence of COVID-19 diagnosis {3.78% [95% confidence interval (CI) 3.69-3.86%] versus 4.53% (95% CI 4.40-4.65%); P < 0.001}. In the 12 344 patients with COVID-19 infection, the use of ACEi/ARBs was not associated with a higher risk of hospitalization with need for invasive respiratory support or death [OR = 0.91 (0.71-1.15); P = 0.426]. RAS blockade in patients with HTN is not associated with higher risk of COVID-19 infection or with a worse progression of the disease
Original languageEnglish
Pages (from-to)79-94
Number of pages16
JournalCKJ: Clinical Kidney Journal
Volume15
DOIs
Publication statusPublished - 2021

Keywords

  • Angiotensin-converting enzyme
  • Angiotensin receptor blockers
  • COVID-19
  • Hypertension
  • Mortality
  • Renin-angiotensin system blockers

Fingerprint

Dive into the research topics of 'Association of renin-angiotensin system blockers with COVID-19 diagnosis and prognosis in patients with hypertension : a population-based study'. Together they form a unique fingerprint.

Cite this